# EcoR1 Capital

> EcoR1 Capital is a San Francisco biotechnology investment adviser founded by Oleg Nodelman. It manages private investment funds that invest in public and private biotechnology companies, combining scientific diligence with business and valuation analysis. Its March 2026 Form ADV reported approximately $3.42 billion in discretionary regulatory assets under management.

- **Founded:** 2012
- **Headquarters:** San Francisco, United States
- **Founders:** Oleg Nodelman (Founder and Portfolio Manager)
- **Products:** Biotechnology investment management, Venture investing, Portfolio-company engagement
- **Notable:** Built a specialist investment manager reporting $3.42 billion in discretionary regulatory AUM in its March 2026 Form ADV., Participated in Scorpion financing before Lilly announced a transaction with potential total consideration of up to $2.5 billion; this is not EcoR1 proceeds or a fund return., Maintains a venture portfolio alongside publicly disclosed biotechnology equity positions.

## Products & services

- **Biotechnology investment management** — Discretionary management of pooled private investment vehicles investing in biotechnology equity and related securities, including public and private holdings.
- **Venture investing** — Capital for private biotechnology companies pursuing therapeutic development, including participation in syndicated financing rounds.
- **Portfolio-company engagement** — Scientific and strategic discussion and selected board participation; Nodelman’s board appointment at Zymeworks was announced in February 2025.

## Achievements

- Built a specialist investment manager reporting $3.42 billion in discretionary regulatory AUM in its March 2026 Form ADV.
- Participated in Scorpion financing before Lilly announced a transaction with potential total consideration of up to $2.5 billion; this is not EcoR1 proceeds or a fund return.
- Maintains a venture portfolio alongside publicly disclosed biotechnology equity positions.

## Latest updates

- **2026-07** — Portfolio company Diagonal announced the first patient dosed in its Phase 1/2 DIAMOND trial of DIAG723 on July 16.
- **2026-06** — Oleg Nodelman pitched Aktis Oncology on All-In’s Best Ideas competition, with his segment beginning at 27:19.
- **2026-03** — Annual Form ADV amendment dated March 30 reported $3,424,668,843 in discretionary regulatory AUM.
- **2026-01** — Diagonal announced a $125 million Series B with EcoR1 as a new investor.

## Links

- Website: https://www.ecor1cap.com/
- LinkedIn: https://www.linkedin.com/company/ecor1-capital-llc

---

Profile page: https://yespress.io/ecor1-capital
Published by YesPress — https://yespress.io
Last updated: 2026-10-27